-
Posted by
Two Blokes Jul 15 -
Filed in
Stock
-
4 views
Oxford BioDynamics PLC (AIM:OBD) shares jumped 66% after Pfizer published data confirming the effectiveness of the company's EpiSwitch blood-based biomarkers in monitoring tumour status and treatment response in bladder cancer patients. The findings, from the JAVELIN Bladder 100 Trial involving 496 patients, were featured in the journal Cancers.
